Morgan Stanley Upgrades Lam Research to Overweight
- Rating
- Buy
- Price target
- $331
- from $293
- Implied upside
- +16%
- vs $284.72 prior close
Morgan Stanley analyst Shane Brett upgraded Lam Research (NASDAQ: LRCX) from Equalweight to Overweight with a price target of $331.00 (from $293.00).
“We’ve preferred DRAM WFE exposure over NAND WFE given the relative revisions, and hence have preferred AMAT over LAM.
The magnitude of our DRAM WFE revisions have narrowed, we’re more positive on NAND WFE revisions from here.
We revise up our CY27 forecast for LAM from $34.6bn/$9.46 to $35.4bn/$9.71 as we now model 59% NAND systems growth, surpassing prior peak in 2021.
We had valued LAM at 31x vs AMAT at 28x, approx. a 10% premium to reflect our confidence on AMAT’s 2026 share gains.
Given our confidence on LAM’s 2027 share gains, we raise that premium to 20%, a touch above the 3-year average of 16%, which brings up our target multiple to 34x and raises our price target from $293 to $331 implying 16% upside.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.
Tracking this call
Since this note+17% LRCX $284.72 → $333.89 (Oct 7) · target reached
This callScored on Nov 17, 2026, six months after the note: did LRCX reach $331?
Firm track recordMorgan Stanley reached 66% of its 53 scored targets within six months (#16 of 31 firms); on Lam Research, 3 of 3. Accuracy ranking →
More from Morgan Stanley on Lam Research
Other Lam Research notes
B RileyBuy
Raised price target +11%, kept rating · Oct 1
$390from $350
UBSBuy
Cut price target −2%, kept rating · Sep 1
$425from $435
MizuhoBuy
Cut price target −1%, kept rating · Aug 25
$365from $370
BernsteinBuy
Raised price target +7%, kept rating · Aug 10
$385from $360
B RileyBuy
Cut price target −9%, kept rating · Jul 30
$350from $385